Can beta blockers cause gynaecomastia? This is a question that arises in clinical practice, given how widely beta blockers are prescribed for hypertension, angina, heart failure, and arrhythmias. Rare case reports and pharmacovigilance data have linked beta blockers to benign male breast tissue enlargement, though the overall risk is considered low and a definitive causal mechanism has not been established. Understanding the evidence, recognising which other medicines carry a stronger association, and knowing when to seek medical advice are all essential for patients and clinicians navigating this concern safely.

Can Beta Blockers Cause Gynaecomastia?

Beta blockers have been linked to gynaecomastia in rare case reports and post-marketing data, but the risk is low and no definitive causal mechanism has been confirmed. Never stop a beta blocker without medical advice due to cardiovascular withdrawal risks.

Gynaecomastia refers to the benign enlargement of glandular breast tissue in males, and it can arise from a range of hormonal, physiological, and drug-related causes. One question that patients and clinicians occasionally raise is whether beta blockers — a widely prescribed class of medicines used to manage conditions such as hypertension, angina, heart failure, and arrhythmias — can contribute to this condition.

The short answer is that beta blockers have been associated with gynaecomastia in rare case reports and pharmacovigilance data, though the overall risk is considered low compared with other drug classes, and a definitive causal link has not been established through large-scale clinical trials. Beta blockers work by blocking the effects of adrenaline at beta-adrenergic receptors, thereby reducing heart rate and blood pressure. The mechanism by which they might contribute to gynaecomastia — if at all — is not established; any hormonal effect is speculative and not confirmed by robust evidence.

Much of the available information comes from individual case reports and post-marketing surveillance data held by regulatory bodies such as the Medicines and Healthcare products Regulatory Agency (MHRA) and the European Medicines Agency (EMA). The NICE Clinical Knowledge Summary (CKS) on Gynaecomastia and the British National Formulary (BNF) are the most relevant UK references for clinicians assessing drug-related causes.

Where gynaecomastia is thought to be drug-induced and the medicine has been taken for a short period (generally less than 12 months), regression following discontinuation is more likely. However, longstanding gynaecomastia may not fully resolve and could require further assessment, including surgical options. Any changes to medication must always be discussed with a healthcare professional first — do not stop your beta blocker without medical advice, as abrupt withdrawal carries cardiovascular risks.

Which Beta Blockers Are Most Commonly Linked to Gynaecomastia?

Propranolol, labetalol, and carvedilol appear most frequently in case reports, but no robust evidence confirms that any specific beta blocker carries a meaningfully higher risk. Consult the relevant SmPC or BNF monograph for individual drug adverse-effect listings.

Rare case reports have described gynaecomastia in patients taking various beta blockers; however, causality is unproven and no robust comparative data exist to reliably rank individual agents by risk. Patients and clinicians should be cautious about drawing firm conclusions regarding which beta blockers are more or less likely to cause this effect.

Some published case reports and post-marketing adverse event data have mentioned propranolol, labetalol, and carvedilol in association with gynaecomastia. Whether these agents carry a meaningfully higher risk than cardioselective beta blockers such as bisoprolol, atenolol, or metoprolol is not established by high-quality evidence. The suggestion that non-selective agents may be more prone to hormonal effects due to their broader receptor profile is plausible but speculative. Selectivity is also not absolute, particularly at higher doses.

Patients and clinicians wishing to check whether gynaecomastia or breast disorders are listed as adverse effects for a specific beta blocker should consult the relevant Summary of Product Characteristics (SmPC) via the MHRA/EMC website or the BNF monograph for that medicine.

Individual patient factors — including age, baseline hormone levels, liver function, and concurrent medications — play a significant role in susceptibility. Older men are more prone to gynaecomastia due to naturally declining testosterone levels, which may make any drug-related hormonal change more clinically apparent.

Patients should not attempt to switch or stop their beta blocker without medical guidance. A GP or cardiologist can assess whether the medication is the likely cause and explore suitable alternatives if necessary.

Other Medicines and Factors That Can Cause Gynaecomastia

Spironolactone, digoxin, anti-androgens, and prolactin-raising medicines such as risperidone carry a more established link to gynaecomastia than beta blockers. Underlying conditions including hypogonadism, hyperthyroidism, and chronic liver disease must also be excluded.

When evaluating gynaecomastia, it is essential to consider the full clinical picture, as beta blockers represent just one of many potential contributing factors. A thorough medication review is a standard part of the diagnostic process, and several other commonly prescribed drug classes are more strongly associated with gynaecomastia than beta blockers.

Medicines with a well-established or recognised link to gynaecomastia include (per NICE CKS and BNF):

• Spironolactone — an aldosterone antagonist widely used in heart failure and resistant hypertension; its anti-androgenic properties can significantly disrupt the oestrogen-to-testosterone ratio

• Digoxin — a cardiac glycoside associated with gynaecomastia in clinical use

• Cimetidine — an older H2 receptor antagonist with anti-androgenic effects

• Finasteride and dutasteride — 5-alpha-reductase inhibitors used for benign prostatic hyperplasia and hair loss

• Anti-androgens and GnRH analogues — including bicalutamide and goserelin, used in prostate cancer treatment

• Ketoconazole — an antifungal that inhibits androgen synthesis

• Anabolic steroids and testosterone therapy — exogenous androgens can be aromatised to oestrogens

• Some antipsychotics and antidepressants — particularly those that raise prolactin levels, such as haloperidol and risperidone

• Domperidone and metoclopramide — dopamine antagonists that raise prolactin

• Verapamil and diltiazem — calcium-channel blockers occasionally associated with gynaecomastia

• Methyldopa — an older antihypertensive

• Efavirenz and some other antiretrovirals

A possible association with proton pump inhibitors (PPIs) has been suggested in some reports, but the evidence is weak and inconsistent; this link should not be assumed without further specialist assessment.

Beyond medications, gynaecomastia can result from underlying medical conditions, including:

• Hypogonadism or testicular disorders

• Hyperthyroidism

• Chronic liver disease (which impairs oestrogen metabolism)

• Renal failure

• Rarely, oestrogen-secreting or hCG-secreting tumours

It is also important to distinguish true gynaecomastia (glandular tissue enlargement) from pseudogynaecomastia (fatty tissue deposition without glandular proliferation), which is associated with obesity and does not carry the same clinical implications.

Physiological gynaecomastia is common during puberty and in older age and does not necessarily indicate pathology. Lifestyle factors such as obesity, excess alcohol consumption, and — according to some reports — cannabis use may also contribute. A comprehensive assessment by a GP will help distinguish drug-induced gynaecomastia from other causes and guide appropriate investigation.

When to Speak to Your GP About Breast Tissue Changes

See your GP promptly for any new breast lump, nipple discharge, asymmetrical swelling, or skin changes, as male breast cancer must be excluded. NICE NG12 recommends an urgent two-week-wait referral for men aged 50 or over with a unilateral firm subareolar mass.

Any new or unexplained change in breast tissue in a male patient warrants prompt medical attention, even if a likely drug-related cause seems apparent. Whilst gynaecomastia is usually benign, it is important to rule out other conditions, including — in rare cases — male breast cancer, which accounts for less than 1% of all breast cancers but should not be overlooked.

You should contact your GP if you notice:

• Swelling, firmness, or a lump beneath one or both nipples

• Breast tenderness or pain

• Nipple discharge of any kind

• Asymmetrical breast changes, particularly if only one side is affected

• Rapid or progressive enlargement of breast tissue

• Skin changes over the breast, such as dimpling or redness

Urgent referral: In line with NICE NG12 (Suspected Cancer: Recognition and Referral), GPs should consider an urgent two-week-wait referral for men aged 50 or over who present with a unilateral, firm subareolar mass with or without nipple discharge. Suspicious features at any age — such as a hard, irregular lump, skin tethering, or axillary lymphadenopathy — should also prompt urgent referral to a breast clinic for triple assessment, regardless of a suspected drug cause.

Your GP will take a detailed history, including a full medication review, and may arrange blood tests to assess hormone levels (including testosterone, oestradiol, LH, FSH, and prolactin), thyroid function, and liver and renal function. Where a germ-cell tumour or other malignancy is suspected, targeted tests such as serum hCG may be arranged, typically with specialist input — routine or generic 'tumour marker' panels are not standard practice in this context. A testicular examination and scrotal ultrasound may also be appropriate if a testicular cause is suspected.

In some cases, an ultrasound or referral to an endocrinologist or breast clinic may be recommended, in line with NICE CKS guidance on gynaecomastia.

It is worth noting that longstanding gynaecomastia (present for more than 12 months) is less likely to regress spontaneously or following medication change, and may require surgical assessment.

It is particularly important not to stop your beta blocker abruptly without speaking to your GP first. Sudden discontinuation can cause rebound hypertension, worsening angina, or cardiac arrhythmias. Your doctor can assess the risk-benefit balance and, if appropriate, arrange a gradual, supervised withdrawal or switch to an alternative agent.

Reviewing Your Medication Safely With NHS Support

Book a GP appointment or structured medication review with a primary care clinical pharmacist to assess whether a beta blocker or other medicine is contributing to gynaecomastia. Suspected adverse reactions can be reported to the MHRA via the Yellow Card scheme.

If you are concerned that a beta blocker or any other medicine may be contributing to gynaecomastia, the NHS offers several avenues for support and medication review. The first and most appropriate step is to book an appointment with your GP, who can assess your symptoms in context and review your full medication list.

In many GP practices, clinical pharmacists are now embedded within primary care networks (PCNs) as part of NHS England's expanded workforce model. These professionals are trained to conduct structured medication reviews and can help identify potential drug interactions or adverse effects, including those related to hormonal changes. They can also liaise with your GP to suggest therapeutic alternatives where appropriate.

Practical steps you can take:

• Bring a complete list of all your medicines, including over-the-counter products and supplements, to your appointment

• Note when you first noticed the breast changes and whether they coincided with starting or changing a medication

• Ask your GP or pharmacist whether any of your medicines are known to affect hormone levels — the BNF and individual medicine SmPCs (available via the MHRA/EMC website) list recognised adverse effects for each drug

• Request a structured medication review if you are taking multiple long-term medicines

• You can also find patient-friendly information about beta blockers and other medicines on the NHS Medicines A–Z

The MHRA Yellow Card scheme allows both patients and healthcare professionals to report suspected adverse drug reactions, including gynaecomastia. Reporting helps build the national evidence base and supports ongoing pharmacovigilance. You can submit a report at yellowcard.mhra.gov.uk.

Ultimately, managing gynaecomastia linked to medication is a collaborative process. With appropriate NHS support, most cases can be effectively assessed and managed, and in many instances, breast tissue changes — particularly those of short duration — may resolve once the causative medicine is adjusted or discontinued under medical supervision.

Frequently Asked Questions